Anemia is a common complication in chronic kidney disease (CKD), and is associated with a
reduced quality of life, and an increased morbidity and mortality. The mechanisms involved …

Anemia and iron deficiency are important and common comorbidities that often coexist in
patients with heart failure. Both conditions, together or independently, are associated with …

Background Among patients with chronic kidney disease (CKD), the use of recombinant
human erythropoietin and its derivatives for the treatment of anemia has been linked to a …

Abstract Background Roxadustat (FG-4592) is an oral inhibitor of hypoxia-inducible factor
(HIF) prolyl hydroxylase that stimulates erythropoiesis and regulates iron metabolism. In …

Background Vadadustat is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor,
a class of drugs that stabilize HIF and stimulate erythropoietin and red-cell production …

In chronic kidney disease, anemia and disordered iron homeostasis are prevalent and
associated with significant adverse consequences. In 2012, Kidney Disease: Improving …

Patients with chronic kidney disease (CKD) are at substantially higher risk for developing
cognitive impairment compared with the general population, and both lower glomerular …

Background Current anemia therapies for patients with non–dialysis-dependent CKD may
require injection and medical visits. Roxadustat, an oral hypoxia-inducible factor prolyl …

Background Intravenous iron is a standard treatment for patients undergoing hemodialysis,
but comparative data regarding clinically effective regimens are limited. Methods In a …

Iron deficiency, even in the absence of anemia, can be debilitating, and exacerbate any
underlying chronic disease, leading to increased morbidity and mortality. Iron deficiency is …